A study of 35 patients undergoing implantation of a newly UK-released Medtronic (NYSE:MDT) LV paving lead, the Attain Stability Quad, reported a 100% successful implantation rate with “reassuring” lead performance and stability data.
Researchers in the study said that further investigation, with more recruitment and follow-ups, would be continuing.
Data from a newly released study of Boston Scientific’s ImageReady implantable cardioverter defibrillator and cardiac resynchronization defibrillator systems during non-diagnostic MR studies showed the devices were safe for scanning.
A total of 159 patients were evaluated, with a 100% complication-free rate reported at 31 days. Study researchers indicated that the ImageReady defibrillator systems were safe for scanning both ICDs and CRT-Ds in 1.5 Tesla systems, when performed under the MR conditions of use.
Data from a study exploring the use of previously used clinically indicated cardiac implantable electronic devices indicates that, unlike previous data had indicated, the use of such devices does not increase the risk of infection, malfunction or death.
Researchers in the study, which explored medical literature on CIED trials between July 1, 2007 and June 30, 2017, explored a total of five studies and 2,114 CIEDs. The primary study outcome was combined risk of infection, malfunction, premature depletion or death as compared to a control group of new CIEDs.
Outcomes indicated that there were no CIED related deaths and no differences between reused and new CIEDs. Investigators suggested that the re-use of such devices could significantly decrease cost and improve CIED use in low-income nations.
Researchers have developed a tool to help with the mapping of atrial fibrillation to help guide AF ablation procedures.
In a pilot study, investigators created maps based off four patients, recording AF data with a 64-pole basket and analyzing electrograms with a novel algorithm. Researchers also developed an iPhone app to be used by physicians in AF procedures.
Results indicated that online mapping software, and an integrated smartphone app were able to help identify sites of persistent AF.
A first-in-man feasibility and safety study exploring the transeptal access rout implantation of EBR System’s WiSE-CRT cardiac resynchronization therapy device reported that the approach was both safe and feasible.